Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. The company has been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India between Fiscal 2017 and 2021. The company is also one of the largest exporters of Salbutamol Sulphate from India in FY 2021 in terms of volume.
In Fiscal 2021, the company’s products were exported to 86 countries to 1,296 customers including 346 distributors. The company has API business in Europe, Latin America, Asia, and North America.
Supriya Lifescience has a modern manufacturing facility in Maharashtra spread across 23,806 sq. mts, having a reactor capacity of 547 KL/ day including 7 clean rooms. The company has also acquired a plot of land, admeasuring 12,551 sq. mt, near the present manufacturing facility, to expand its manufacturing infrastructure. The company’s manufacturing facility has received approvals from USFDA, EDQM TGA-Australia, KFDA-Korea, PMDA Japan, NMPA (previously known as SFDA)- China, Health Canada, in relation to API products being exported to the relevant jurisdictions by the company.
Company Promoters:
Satish Waman Wagh is the company promoter.
Company Financials:
| Particulars | For the year/period ended (₹ in Millions) | |||
|---|---|---|---|---|
| 30-Sep-21 | 31-Mar-21 | 31-Mar-20 | 31-Mar-19 | |
| Total Assets | 5,041.02 | 4,458.24 | 3,364.01 | 2,530.52 |
| Total Revenue | 2,300.61 | 3,962.21 | 3,227.13 | 2,858.62 |
| Profit After Tax | 659.59 | 1,238.28 | 733.74 | 394.24 |
Objects of the Issue:
- Funding capital expenditure requirements of the company
- Repayment and/ or pre-payment, in full or part, of certain borrowings availed by the company and
- General corporate purposes
Supriya Lifescience IPO Details
| IPO Opening Date | Dec 16, 2021 |
| IPO Closing Date | Dec 20, 2021 |
| Issue Type | Book Built Issue IPO |
| Face Value | ₹2 per equity share |
| IPO Price | [.] to [.] per equity share |
| Market Lot | |
| Min Order Quantity | |
| Listing At | BSE, NSE |
| Issue Size | [.] Eq Shares of ₹2 (aggregating up to ₹700.00 Cr) |
| Fresh Issue | [.] Eq Shares of ₹2 (aggregating up to ₹200.00 Cr) |
| Offer for Sale | [.] Eq Shares of ₹2 (aggregating up to ₹500.00 Cr) |
Supriya Lifescience IPO Tentative Timetable
The Supriya Lifescience IPO open date is Dec 16, 2021, and the close date is Dec 20, 2021. The issue may list on Dec 28, 2021.
| IPO Open Date | Dec 16, 2021 |
| IPO Close Date | Dec 20, 2021 |
| Basis of Allotment Date | Dec 23, 2021 |
| Initiation of Refunds | Dec 24, 2021 |
| Credit of Shares to Demat Account | Dec 27, 2021 |
| IPO Listing Date | Dec 28, 2021 |
Supriya Lifescience IPO Promoter Holding
| Pre Issue Share Holding | 99.98% |
| Post Issue Share Holding |
Company Contact Information
Supriya Lifescience Limited
207/208, Udyog Bhavan,
Sonawala Road, Goregaon,
East, Mumbai – 400063, Maharashtra, India
Phone: +91-22-40332727
Email: cs@supriyalifescience.com
Website: https://supriyalifescience.com/
Supriya Lifescience IPO Registrar
Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: supriyalife.ipo@linkintime.co.in
Website: https://linkintime.co.in/